Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 19.7% in Chronic+Subchronic and 13.7% in Acute therapy segment. Our field force productivity of INR 4.1 Lac (YPM – Yield per Man per Month) is industry-leading and we are amongst the most productive companies in the Industry.Our product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists. Super specialists and specialists contribute to 86.3% of our total prescriptions as compared to 62.6% for the IPM.